Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Laurent Sulpice

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8817-1685; OpenAlex author ID A5028991619. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2015: 2 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 3 papers

Papers 10

  1. Preservation of EUS-guided gastrojejunostomy LAMS during pancreaticoduodenectomy: a paradigm shift in the surgical management of borderline resectable pancreat… Last author DOI 10.1007/s13304-025-02380-1↗
  2. Correction: Preservation of EUS-guided gastrojejunostomy LAMS during pancreaticoduodenectomy: a paradigm shift in the surgical management of borderline resecta… Last author DOI 10.1007/s13304-025-02424-6↗
  3. Para-aortic lymph nodes in oligometastatic pancreatic ductal adenocarcinoma. Last author DOI 10.1016/s1470-2045(26)00182-8↗
  4. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  5. Multi-visceral resection for left-sided pancreatic ductal adenocarcinoma: a multicenter retrospective analysis from European countries. Co-author DOI 10.1007/s00423-023-03110-0↗
  6. The Oncologic Impact of Pancreatic Fistula After Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma of the Body and the Tail: A Multicenter Retrospecti… Co-author DOI 10.1245/s10434-020-09310-y↗
  7. Molecular profiling of stroma highlights stratifin as a novel biomarker of poor prognosis in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41416-020-0863-1↗
  8. Reply to the Letter to the Editor "Laparoscopic Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: time for a Randomized Controlled Trial? Results of … First author DOI 10.1097/sla.0000000000001709↗
  9. Complete radiological response of an initially locally advanced unresectable pancreatic cancer to chemoradiotherapy using FOLFIRINOX regimen: report of a case. Last author DOI 10.1016/j.clinre.2014.08.011↗
  10. Laparoscopic Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: Time for a Randomized Controlled Trial? Results of an All-inclusive National Observati… Co-author DOI 10.1097/sla.0000000000001479↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fabien Robin · 3 shared papers, 2020–2026 · strength 0.97
  2. Raffaele Vincenzo De Rosa · 2 shared papers, 2026 · strength 0.86
  3. Hector Prudhomme · 1 shared paper, 2026 · strength 0.50
  4. Mircea Chirica · 2 shared papers, 2021–2023 · strength 0.25
  5. Patrick Pessaux · 2 shared papers, 2021–2023 · strength 0.25
  6. Tullio Piardi · 2 shared papers, 2021–2023 · strength 0.25
  7. Fabrizio Panaro · 2 shared papers, 2021–2023 · strength 0.25
  8. Piera Leon · 2 shared papers, 2021–2023 · strength 0.25
  9. Ugo Boggi · 2 shared papers, 2021–2023 · strength 0.25
  10. Massimo Falconi · 2 shared papers, 2021–2023 · strength 0.25
  11. Noelle Bendersky · 2 shared papers, 2015–2017 · strength 0.17
  12. Olivier Farges · 2 shared papers, 2015–2017 · strength 0.17
  13. Edoardo Rosso · 1 shared paper, 2023 · strength 0.15
  14. Cecilia Ferrari · 1 shared paper, 2023 · strength 0.15
  15. Riccardo Memeo · 1 shared paper, 2023 · strength 0.15
  16. Fabio Giannone · 1 shared paper, 2021 · strength 0.10
  17. Giulio Belfiori · 1 shared paper, 2021 · strength 0.10
  18. Andrea Gardini · 1 shared paper, 2021 · strength 0.10
  19. Stefano Crippa · 1 shared paper, 2021 · strength 0.10
  20. Jean‐Robert Delpéro · 1 shared paper, 2015 · strength 0.06
  21. Safi Dokmak · 1 shared paper, 2015 · strength 0.06
  22. Alain Sauvanet · 1 shared paper, 2015 · strength 0.06
  23. Kathleen Turner · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.